PERTH, Australia – Adelaide, Australia-based Bionomics Inc. reported another trial failure with its lead compound, BNC-210, in elderly patients with agitation, but it is still clinging on to hopes that the compound will show a clinical benefit for post-traumatic stress disorder (PTSD). Read More
HONG KONG – To improve public health care in Brazil, Bioneer Corp., a South Korean biotech, and Brazilian government-run Institute of Technology on Imunobiologicals (Bio-Manguinhos) will focus on business development and R&D of in vitro diagnostics and new drugs. Read More
HONG KONG – Incyte Corp. entered a collaboration and licensing deal to flip its greater China rights to an investigational anti-PD-1 monoclonal antibody to Zai Lab Ltd., of Shanghai. The candidate, INCMGA-0012, is currently being evaluated as a monotherapy in registration-directed trials for patients with MSI-high endometrial cancer, Merkel cell carcinoma and anal cancer. Read More
Keeping with the trend of high-value biopharma deals, the second quarter of 2019 logged another eight partnerships worth $1 billion or more, with Gilead Sciences Inc. a party to three of them. Read More
In what may be the smallest double-blind, placebo-controlled clinical trials on record, researchers have shown that treating two individuals with drugs aimed at raising brain levels of glycine improved their psychotic symptoms. Read More
Researchers have shown that by using a combination of genome editing and long-acting slow-effective release antiviral therapy (LASER ART), they were able to eradicate HIV reservoirs and cure nearly 40% of HIV-infected mice. Read More
Prestige Biopharma Pte. Ltd., of Singapore, and Moscow, Russia-based Pharmapark LLC said they entered a binding agreement for the exclusive partnership and supply for the commercialization of Prestige's trastuzumab biosimilar in the Russian Federation. Read More
